A role for EMT in CD73 regulation in breast cancer

Meriem Hasmim, Guy Berchem, Bassam Janji*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review


CD73 is an emerging target in cancer due to its role in generating adenosine, a potent immunosuppressor. We found that SNAI1, a driver of epithelial-to-mesenchymal transition (EMT), upregulates CD73 in triple negative breast cancer cells. Here, we discuss the relevance of improving CD73-based therapy by combining with inhibitors of EMT.

Original languageEnglish
Article number2152636
Issue number1
Publication statusPublished - 30 Nov 2022


  • Humans
  • Epithelial-Mesenchymal Transition
  • Triple Negative Breast Neoplasms/genetics
  • Adenosine


Dive into the research topics of 'A role for EMT in CD73 regulation in breast cancer'. Together they form a unique fingerprint.

Cite this